FDA Grants Accelerated Approval to the Combination of Avutometinib and Defactinib for KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer By Ogkologos - May 30, 2025 700 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the RAMP-201 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Lurbinectedin Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian MOST POPULAR Vepdegestrant Prolongs PFS in a Subgroup of Patients with ER-positive, HER2-negative... June 30, 2025 News digest – light-activated nanoparticles, Government’s obesity plans, tumour ‘glue’ and... July 11, 2020 Zero Mutation ctDNA Triage for Selection of Patients with Metastatic Colorectal... August 17, 2022 Cancer Research UK’s Race for Life celebrates its 30th year by... April 24, 2023 Load more HOT NEWS EMA Adopts a Positive Opinion for a New Indication for Pembrolizumab Coping With the Difficult Times of Cancer Survivorship Through My “Bucket... Marine Runs Five Marathons in Five Days to Help Fund Sister’s... The vaccination of a generation? – That Cancer Conversation
